Targeted Therapy

Cancer cells depend on signals that tell them to grow. A targeted drug blocks one of those signals, flags a protein on the cell so the immune system can see it, or interferes with a repair weakness the cancer cannot do without. The drug is chosen because the tumour has that feature. Chemotherapy, by contrast, affects many dividing cells and does not need a matching mutation. Both approaches are used in modern care. One is not a moral improvement on the other. The right one is the one the reports support.

Examples patients commonly hear include HER2 antibodies and tablets in HER2-positive breast cancer, EGFR, ALK, and ROS1 inhibitors in some lung cancers, anti-EGFR antibodies in selected bowel cancers, PARP inhibitors in some ovarian cancers with a BRCA-related weakness, and BCR-ABL tablets in chronic myeloid leukemia. Each example applies only when the test matches. Using them outside that match exposes you to side effects without a reason to expect benefit.

Testing is most useful when the result could change treatment. The useful panel depends on the cancer type and stage. A large test ordered without a plan can add cost, delay, and results that nobody can act on. A variant of unknown significance is not a target. A hereditary test, such as BRCA in a blood sample, answers a different question from a test done on the tumour, and it can have meaning for relatives. Those conversations should happen before the sample is sent.

Tissue from the biopsy is the usual source. A blood test for tumour DNA can help when a biopsy is hard to repeat, and it can miss a change that is sitting in the tumour. If a previous hospital has already tested the cancer, bring that report. Repeating an identical test wastes time. If the cancer has grown through a targeted drug, a new test sometimes looks for a resistance mutation before the next drug is chosen. That step is specific to the cancer and the first drug.

Many targeted medicines are tablets taken at home. Others are infusions in clinic, especially monoclonal antibodies. Oral treatment is convenient and easy to underestimate. Missed doses, food instructions, and interactions with stomach-acid medicines, antibiotics, or herbal products can change how much drug reaches the cancer. You should leave clinic with a missed-dose rule written down. Guessing, or doubling the next dose, is unsafe.

Side effects depend on the target, not on a shared list. Rash and diarrhoea are common with EGFR blockers. High blood pressure, hand-foot soreness, and poor wound healing occur with several drugs that affect blood vessels. Liver tests, heart rhythm, and blood counts need checking with particular tablets. HER2 antibodies can affect the heart, so heart function is monitored. PARP inhibitors can lower blood counts. None of these effects means you should stop the drug silently. A dose reduction or a short pause is often how treatment stays possible. Report the symptom and let the clinic make that change.

When a targeted drug matches, scans may show shrinkage or a long period of stability. Symptoms such as cough, pain, or jaundice may ease. That is the aim in advanced disease: control for as long as the benefit outweighs the burden. It is not a promise of cure. Resistance can develop. The cancer finds another way to grow. When that happens, the next choice may be a different targeted drug, chemotherapy, a clinical trial, or a focus on comfort. The first drug’s success does not entitle anyone to an endless sequence of equally effective drugs.

In early breast cancer, HER2-directed treatment and some other targeted drugs are used with curative intent alongside chemotherapy and surgery. The goal there is different from the goal in metastatic disease, and the duration is defined. Finishing the planned course matters. Stopping because the hair has regrown or the scar has healed can undo part of the benefit. Ask how long the plan lasts before you start, and what would justify stopping early.

Bring every prescription and supplement to each visit, including medicines started by another doctor for blood pressure, infection, or pain. Some targeted drugs interact with common antibiotics and antifungals. Grapefruit and certain herbal products matter for some tablets. Pregnancy must be avoided with most of these medicines. Contraception advice should be specific. If you need an operation or dental work, tell both teams, because some drugs affect wound healing and should be paused.

Cost and availability are practical parts of the decision. A drug that exists in a guideline but cannot be obtained reliably is not a real plan. The consultation should say what is appropriate and what is actually accessible, and what the alternative is. Buying cancer tablets from an unverified source is dangerous. Doses and storage conditions are part of the medicine. So is the follow-up that catches toxicity.

Precision oncology means using receptors, gene changes, and other biomarkers to choose among treatments more carefully. Targeted therapy is one result of that approach. Sometimes the precise result is that no target is present and standard chemotherapy or hormone therapy remains the right plan. That is a useful result. It saves you from a drug that would not help. Dr. Nishith Vaddeboina’s clinical work includes oral anticancer medicines, their indications, and their toxicities. Whether a tablet is appropriate still depends entirely on your reports.

Ask which result the drug depends on, and ask to see that line in the report. Ask what a negative or uncertain result means, and whether another test is still worth doing. Ask how many hours from food the tablet must be taken, what a missed dose looks like, and which pharmacy or stomach medicines clash with it. Ask which blood tests are due before the next visit, and what rash, diarrhoea, or blood-pressure readings should interrupt treatment.

Ask the goal in one sentence: cure as part of a longer plan, longer control of advanced disease, or symptom relief. Ask how resistance would be recognised and what the options usually are after that, without expecting a promise. Bring a complete medicine list, including supplements bought without a prescription. Oral targeted therapy fails quietly when doses are missed or combined with the wrong antibiotic. The monitoring plan is what makes a home tablet a cancer treatment rather than an unsupervised experiment.

If the recommended drug is difficult to obtain, ask for the evidence-based alternative that you can actually take, and for how the two differ in benefit and side effects. A plan that exists only on paper will not help. Do not fill the gap with medicines bought online. Dosing errors and fake products cause real harm, and they remove the clinic’s ability to judge toxicity. The consultation should end with a drug name, a dose, a test date, and a phone number.

A visit about targeted therapy is used to read the records you already have, explain them in plain language, and outline options that may apply. Bring the biopsy or pathology report, scan CDs or reports, blood tests, and a list of treatment already given, including dates and drug names if you have them. A family member can come with you. The visit is not an emergency assessment, and it does not confirm a plan until the records have been reviewed.

Dr. Nishith Vaddeboina is a medical oncologist. Appointments published on this website are at American Oncology Institute, Nallagandla, Hyderabad. The biography also lists consultant work at Renova Century Hospitals. Confirm the hospital when you book. Plans are discussed against recognised guidance, including NCCN, ESMO, and ASCO, and then adjusted to the person in the room. Nothing on this page replaces that conversation.